GALECTIN-3 INHIBITOR (GAL-3M) IS ASSOCIATED WITH ADDITIVE ANTI-MYELOMA AND ANTI-SOLID TUMOR EFFECTS, DECREASED OSTEOCLASTOGENESIS AND ORGAN PROTECTION WHEN USED IN COMBINATION WITH PROTEASOME INHIBITORS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 6, 2015
app pub date -
Feb 3, 2015
filing date -
Feb 3, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully